My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer - Episode 8

Ongoing Trial(s) for Intracranial Progression in Advanced HER2+ Breast Cancer

February 4, 2025

Panelists discuss the design and rationale of the ongoing BRIDGET (NCT05323955) trial, focusing on how its outcomes could potentially shape the future treatment landscape for HER2-positive breast cancer, particularly in patients with brain metastases.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets

EP. 2: Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases

EP. 3: T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets

EP. 4: The Impact of Trastuzumab Deruxtecan on Clinical Practice for HER2+ Advanced BC and Brain Mets

EP. 5: The Influence of Systemic Metastases on Treatment Decision-Making for HER2+ BC With Brain Metastases

EP. 6: Management of HER2+ Breast Cancer With Brain Relapse or Progression

EP. 7: HER2CLIMB-02 Trial: Exploring Tucatinib and T-DM1 for HER2+ mBC

Now Viewing

EP. 8: Ongoing Trial(s) for Intracranial Progression in Advanced HER2+ Breast Cancer

EP. 9: Novel and Emerging Therapeutic Strategies for HER2+ Breast Cancer and Brain Metastases

Video content above is prompted by the following:

Briefly review the design and rationale for the ongoing BRIDGET (NCT05323955) trial, and how could the outcomes of this trial shape the future treatment landscape?